Stockscreener 앱 받기
0.7743
0.83%
0.0064
시간 외 거래:
.77
-0.0043
-0.56%
전일 마감가:
$0.7679
열려 있는:
$0.751
하루 거래량:
20.93M
Relative Volume:
5.11
시가총액:
$225.57M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-2.0927
EPS:
-0.37
순현금흐름:
$-72.53M
1주 성능:
-9.69%
1개월 성능:
-15.70%
6개월 성능:
-39.74%
1년 성능:
+103.60%
1일 변동 폭
$0.73
$0.7999
1주일 범위
$0.73
$0.89
52주 변동 폭
$0.37
$2.105
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
OCGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.7743 | 225.57M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Ocugen Inc. stock rises Friday, still underperforms market - MarketWatch
Ocugen to Present at Oppenheimer Movers in Rare Disease Summit - MSN
Ocugen’s Gene Therapy Trial for Dry AMD Advances - MyChesCo
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen
Ocugen's Eye Treatment Shows Promising Safety Data in Phase 1/2 Trial for Macular Degeneration - StockTitan
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Oppenheimer Movers in Rare Disease Summit - Ocugen
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - Ocugen
Ocugen CEO to Showcase Breakthrough Gene Therapy Programs at Oppenheimer Rare Disease Summit - StockTitan
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference - Ocugen
Ocugen, Inc. to Present at NobleCon20 Emerging Growth Equity Conference - MSN
ocugen director Fernandes buys $9,095 in common stock - Investing.com
ocugen director Fernandes buys $9,095 in common stock By Investing.com - Investing.com Australia
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference - Ocugen
Ocugen CEO to Present Clinical Program Updates at NobleCon20 Conference | OCGN Stock News - StockTitan
Ocugen director Kirsten Castillo buys $22,847 in stock - Investing.com India
Ocugen director Kirsten Castillo buys $22,847 in stock By Investing.com - Investing.com Australia
Ocugen Reports Promising Results from OCU410 ArMaDa Trial for Geographic Atrophy - MSN
Ocugen Secures EMA Orphan Designation for OCU410ST, Advancing Stargardt Disease Treatment - MSN
Ocugen Announces European Medicines Agency Grants Orphan - GlobeNewswire
Ocugen reports positive data for OCU400, OCU410 - MSN
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen announces EMA granted orphan medicinal product designation for OCU410ST - TipRanks
Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 - MSN
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease - The Manila Times
Ocugen's Eye Disease Drug Shows 84% Lesion Reduction, Receives EMA Orphan Status | OCGN Stock News - StockTitan
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy - Ophthalmology Times
Ocugen announces preliminary efficacy, safety data from Phase 1/2 OCU410 trial - TipRanks
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen
Ocugen Announces Compelling Preliminary Data for OCU410—a - GlobeNewswire
Ocugen's Eye Treatment Shows 21% Disease Slowdown in Phase 1 Trial Data | OCGN Stock News - StockTitan
OCGN Stock: Can New Leadership Save This Biotech Company? - TipRanks
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Appoints Ramesh Ramachandran as Financial Officer - TipRanks
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
오큐젠 주식 (OCGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Castillo Kirsten | Director |
Nov 22 '24 |
Buy |
0.91 |
25,000 |
22,848 |
75,000 |
2.88%
2.65%
자본화:
|
볼륨(24시간):